close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

2.360 +0.020 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jasper Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
JASPER LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Jasper Investors to Contact the Firm Regarding Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
JSPR INVESTOR ALERT: Bronstein, Gewirtz &amp; Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
From Faruqi & Faruqi LLP
Via GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Approaching: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR
From Faruqi & Faruqi LLP
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR
From Pomerantz LLP
Via GlobeNewswire
Law Offices of Howard G. Smith Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
Law Offices of Frank R. Cruz Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
JASPER ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Jasper Therapeutics, Inc. (JSPR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
From DJS Law Group
Via Business Wire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged to Contact the Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
From Faruqi & Faruqi, LLP
Via Business Wire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Jasper Reports Wider Loss in Fiscal Q2
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today